More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

Nanoparticles to Significantly Enhance Cerenkov Luminescence

SK2014-082

SUMMARY OF INVENTION

MSK investigators have developed a novel method of imaging tissue in a preclinical or clinical setting to enhance Cerenkov luminescence from radiotracers without increasing radionuclide dose. This method involves coupling a radionuclide to a nanoparticle (i.e. silica nanoparticle or liposome). Since light is refracted from nanoparticles more so than tissue, the resulting Cerenkov light is stronger for radionuclides coupled to nanoparticles, compared to radionuclides alone. By enhancing the brightness and imaging potential, this method will significantly increase the benefits associated with Cerenkov luminescence-oriented systems.

BACKGROUND

Cerenkov luminescence describes a weak light that is emitted when a particle travels through a medium at a velocity faster than the speed of light travels through the medium. The light emitted from Cerenkov luminescence is weaker in mediums through which light can pass more easily compared to mediums through which light is more refracted.

In medical settings, radionuclides traveling through serum and tissue can produce Cerenkov light. This allows for a radiotracer to be detected with two independent modalities – optical and PET imaging. Advantages of this dual imaging system include that optical cameras are much less expensive than PET imaging instruments, and radionuclides that are difficult to image in vivo could be imaged using Cerenkov luminescence. However, the level of light emitted is low and the detection of Cerenkov luminescence requires a highly sensitive device, thereby limiting the potential applications of this technology in preclinical or clinical settings. This novel method enables a stronger Cerenkov luminescent image than was previously possible.

ADVANTAGES

  • Proprietary method for enhancing Cerenkov luminescence using nanoparticles

  • Allows for expanded use of Cerenkov luminescence which will facilitate broader applications of preclinical and clinical imaging

MARKET OPPORTUNITIES

This novel method could expand the benefits and potential use of Cerenkov luminescence for broad applications, including both preclinical and clinical imaging.

STAGE OF DEVELOPMENT

Preclinical

PATENT INFORMATION

PCT application filed on February 17, 2016

LEAD INVESTIGATOR

Jan Grimm, PhD, Laboratory Head, Molecular Pharmacology Program, Sloan Kettering Institute, MSK

CONTACT INFORMATION

Eileen Flowers, PhD, Licensing Manager
Tel: 646-888-1067
E-mail:
flowerse@mskcc.org

Stage of Development

In vitro

Indications

Types